Advanced search
Publication Cover
Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration Volume 18, 2017 - Issue sup1: Edaravone (MCI-186) in Amyotrophic Lateral Sclerosis (ALS). Guest Editor: Angela Genge
Submit an article Journal homepage
4,040
Views
27
CrossRef citations to date
0
Altmetric
Clinical Trial

Exploratory double-blind, parallel-group, placebo-controlled extension study of edaravone (MCI-186) in amyotrophic lateral sclerosis

THE WRITING GROUP ON BEHALF OF THE EDARAVONE (MCI-186) ALS 17 STUDY GROUP
Pages 20-31 | Received 27 Mar 2017, Accepted 26 Jul 2017, Published online: 05 Sep 2017

References

  • Beckman JS, Carson M, Smith CD, Koppenol W. ALS, SOD and peroxynitrite. Nature. 1993;364:584.
  • Abe K, Itoyama Y, Sobue G, Tsuji S, Aoki M, Doyu M, et al. Confirmatory double-blind, parallel-group, placebo-controlled study of efficacy and safety of edaravone (MCI-186) in amyotrophic lateral sclerosis patients. Amyotroph Lateral Scler Frontotemporal Degener. 2014;15:610–17.
  • Cedarbaum JM, Stambler N, Malta E, Fuller C, Hilt D, Thurmond B, et al. The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function. J Neurol Sci. 1999;169:13–21.
  • Ohashi Y, Tashiro K, Itoyama Y, Nakano I, Sobue G, Nakamura S, et al. Study of functional rating scale for amyotrophic lateral sclerosis: revised ALSFRS (ALSFRS-R) Japanese version. No to Shinkei. 2001;53:346–55. Japanese.
  • The Edaravone (MCI-186) ALS 16 Study Group. A post-hoc subgroup analysis of outcomes in the first phase III clinical study of edaravone (MCI-186) in amyotrophic lateral sclerosis. Amyotroph Lateral Scler and Frontotemporal Degener. 2017;18 (Suppl). Epub ahead of print. doi. 10.1080/21678421.2017.1363780.
  • Norris FH Jr, Calanchini PR, Fallat RJ, Panchari S, Jewett B. The administration of guanidine in amyotrophic lateral sclerosis. Neurology. 1974;24:721–8.
  • Oda E, Ohashi Y, Tashiro K, Mizuno Y, Kowa H, Yanagisawa N. Reliability and factorial structure of a rating scale for amyotrophic lateral sclerosis. No to Shinkei. 1996;48:999–1007. Japanese.
  • Jenkinson C, Fitzpatrick R, Brennan C, Swash M. Evidence for the validity and reliability of the ALS assessment questionnaire: The ALSAQ-40. Amyotroph Lateral Scler Other Motor Neuron Disord. 1999;1:33–40.
  • Yamaguchi T, Ohbu S, Saito M, Ito Y, Moriwaka F, Tashiro K, et al. Validity and clinical applicability of the Japanese version of amyotrophic lateral sclerosis –assessment questionnaire 40 (ALSAQ-40). No to Shinkei. 2004;56:483–94. Japanese.
  • Terao S, Miura N, Osano Y, Adachi K, Sobue G. Clinical characteristics of elderly Japanese patients with amyotrophic lateral sclerosis; with special reference to the development of respiratory failure. Clin Neurol. 2006;46:381–9. Japanese.
  • Magnus T, Beck M, Giess R, Puls I, Naumann M, Toyka KV. Disease progression in amyotrophic lateral sclerosis: predictors of survival. Muscle Nerve. 2002;25:709–14.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.